Published On: Wed, Oct 19th, 2016

Incyte Corporation (NASDAQ:INCY) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of Incyte Corporation (NASDAQ:INCY).

Most recent broker ratings

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Cowen.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 98 price target on the stock.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 116 price target on the stock.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 121 price target on the stock.

09/29/2016 – Incyte Corporation was upgraded to “outperform” by analysts at Raymond James. They now have a USD 115 price target on the stock.

09/26/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Argus. They now have a USD 98 price target on the stock.

08/16/2016 – Incyte Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 102 price target on the stock.

08/10/2016 – Incyte Corporation had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 100 price target on the stock.

08/05/2016 – SunTrust began new coverage on Incyte Corporation giving the company a “buy” rating. They now have a USD 105 price target on the stock.

06/29/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Goldman Sachs.

06/14/2016 – Incyte Corporation had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 100 price target on the stock.

04/18/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 88 price target on the stock.

03/23/2016 – Morgan Stanley began new coverage on Incyte Corporation giving the company a “overweight” rating. They now have a USD 85 price target on the stock.

02/12/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at UBS. They now have a USD 88 price target on the stock.

02/12/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 108 price target on the stock.

The share price of Incyte Corporation (NASDAQ:INCY) was up +2.40% during the last day of trading, with a day high of 89.79. 1067365 shares were traded during the last session.

The stock’s 50 day moving average is 87.09 and its 200 day moving average is 81.92. The stock’s market capitalization is 16.69B. Incyte Corporation has a 52-week low of 55.00 and a 52-week high of 124.98.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.